Faculty

Institution

Unit

Venue

Nicholas Jennings

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

NoneNicholas Jennings is currently serving as a Gynecologic Oncology And Reproductive Medicine faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Nicholas Jennings

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

ovarian cancer cancer biology oncology tumor biology gynecologic oncology pharmacology cancer research cell biology medicinal research cancer cells oncogenes cancer treatment immunology tumor targeting gynecologic cancers therapeutic targets radiation oncology cancer growth cancer immunotherapy molecular cancer ovarian carcinoma vascular biology cellular therapy cancer care cancer discovery cancer genetics drug targeting anti-cancer agents enzyme inhibition tumor growth cell regulation angiogenesis clinical research endocrine oncology tumor suppressors ovarian cancer cells cancer management extracellular microvesicles endothelial cells ovarian cancer growth matrix biology cytokines fibroblast growth factors immune checkpoint inhibitors hematological malignancies adaptive resistance clinical investigation surgical oncology biological chemistry cancer imaging cancer letter cancer risk endocrine-related cancers cancer immunosurveillance viral oncology biological function focal adhesion kinase ovarian carcinoma growth cystathionine beta-synthase ovarian cancer progression clinical effectiveness clinical medicine clinical reviews clinical physiology immunoediting clinical radiation oncology molecular regulation functional modification ovarian hormones prognosis tumor angiogenesis adrenergic modulation vivo tumor growth il-8 gene depressive symptoms cortisol rhythmicity

Notable Scholarly Works

Notable Federal Grants

Collaborators

Epigenetic Modulation of Bard1 to Enhance Anti-Vegf Therapy. Cell Reports Medicine (2025)

cell biologyoncogenesfibroblast growth factorsepigenetic modulationmolecular medicine

Abstract 3847: Dual Targeting of Egfl6 and Vegf-a to Overcome Immune Suppression in Ovarian Cancer. Cancer Research (2024)

Sujanitha UmamaheswaranLingegowda S. MangalaRobiya JosephNicholas B. JenningsMark S. KimYunfei WenEmine BayraktarNingyan ZhangZhiqiang AnAnil K. Sood

cancer researchcancer biologyovarian cancerimmunologyimmune suppression

Mechanism and Rational Combinations With Gp ‐2250, a Novel Oxathiazine Derivative, in Ovarian Cancer. Cancer Medicine (2024)

cancer letterchemoprevention strategiescancer researchovarian canceroncogenic agentanti-cancer agentrational combinationsnovel oxathiazine derivativebiochemistrypharmacologycancer cellcancer discoverygynecologic oncologyendocrine-related cancertherapeutic target

Abstract 2720: Enhancing Oral Delivery of Plant-Derived Vesicles. Cancer Research (2023)

Yuan LiuAdrian Lankenau-AhumadaEmine BayraktarPaul SchwartzMamur ChowdhurySixiang ShiManu M. SebastianHtet KhantNatalia De ValZuliang JieNicholas B. JenningsCristian Rodriguez-AguayoJody SwainElaine SturLingegowda S. MangalaYutuan WuSupriya NagarajuBrooke ErimasChun LiGabriel Lopez-BeresteinJanet BraamAnil K. Sood

plant-derived vesiclesoncologycancer researchcancer biologycancer carebiotechnologyhealth sciencesoral deliverydrug delivery

Abstract 528: Mechanisms and Rational Combinations With Gp-2250, a Novel Oxathiazine Derivative, in Ovarian Cancer. Cancer Research (2023)

Mark S. KimDeanna GlassmanAdrian Lankenau AhumadaEmine BayraktarNicholas B. JenningsRobiya JosephSanghoon LeeRobert L. ColemanAnil K. Sood

cancer researchcancer biologyovarian cancerbiochemistrygynecologic oncologynovel oxathiazine derivative

Data From Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. (2023)

Ju-Won RohJie HuangWei HuXiaoYun YangNicholas B. JenningsVasudha SehgalBo Hwa SohnHee Dong HanSun Joo LeeDuangmani ThanapprapasrJustin Bottsford-MillerBehrouz ZandHeather J. DaltonRebecca A. PrevisAshley N. DavisKoji MatsuoJu-Seog LeePrahlad RamRobert L. ColemanAnil K. Sood

gynecologytumor biologyuterine cancercancer biologycell biologybiologic effectspharmacology

Data From Cross-Talk Between Epha2 and Braf/Craf is a Key Determinant of Response to Dasatinib. (2023)

Jie HuangWei HuJustin Bottsford-MillerTao LiuHee Dong HanBehrouz ZandSunila PradeepJu-Won RohDuangmani ThanapprapasrHeather J. DaltonChad V. PecotRajesh RupaimooleChunhua LuBryan FellmanDiana UrbauerYu KangNicholas B. JenningsLi HuangMichael T. DeaversRussell BroaddusRobert L. ColemanAnil K. Sood

protein sciencecell signalingkey sitepharmacologymulti-omics studiesgene expressionkey determinantproteomicscancer discoveryclinical proteomicsvariant interpretationimmune responsesfeedback loopimmunologymedicinal researchepigeneticsproteome researchepigenomicsmolecular biology

Data From Dll4 Inhibition Plus Aflibercept Markedly Reduces Ovarian Tumor Growth. (2023)

Jie HuangWei HuLimin HuRebecca A. PrevisHeather J. DaltonXiao-Yun YangYunjie SunMichael McGuireRajesha RupaimooleArchana S. NagarajaYu KangTao LiuAlpa M. NickNicholas B. JenningsRobert L. ColemanRobert B. JaffeAnil K. Sood

gynecologygynecologic cancerscancer biologytumor suppressorstumor biologyovarian tumor growthcancer researchoncologysystems biologycancer discoveryanti-cancer agentsovarian cancermedicinal researchgynecologic oncologycancer growthcancer cellsoncogenesmolecular biologycancer genetics

Data From Epha2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma. (2023)

Jeong-Won LeeRebecca L. StoneSun Joo LeeEun Ji NamJu-Won RohAlpa M. NickHee-Dong HanMian M.K. ShahzadHye-Sun KimLingegowda S. MangalaNicholas B. JenningsShenlan MaoJohn GooyaDowdy JacksonRobert L. ColemanAnil K. Sood

cancer immunotherapygynecologic cancersoncologycancer researchendometrial carcinomaimmunologycancer treatmentdrug targetingtumor targetingantibody drug conjugategynecologic oncology

Data From Immunotherapy Targeting Folate Receptor Induces Cell Death Associated With Autophagy in Ovarian Cancer. (2023)

Yunfei WenWhitney S. GraybillRebecca A. PrevisWei HuCristina IvanLingegowda S. MangalaBehrouz ZandAlpa M. NickNicholas B. JenningsHeather J. DaltonVasudha SehgalPrahlad RamJu-Seog LeePablo E. Vivas-MejiaRobert L. ColemanAnil K. Sood

cancer immunotherapycell autophagyovarian cancerautophagyimmunotherapyimmunologyfolate receptor inducescell death

1
2
3
4
5
10
10 / page

Nicholas Jennings

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

NoneNicholas Jennings is currently serving as a Gynecologic Oncology And Reproductive Medicine faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Nicholas Jennings

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Epigenetic Modulation of Bard1 to Enhance Anti-Vegf Therapy. Cell Reports Medicine (2025)

cell biologyoncogenesfibroblast growth factorsepigenetic modulationmolecular medicine

Abstract 3847: Dual Targeting of Egfl6 and Vegf-a to Overcome Immune Suppression in Ovarian Cancer. Cancer Research (2024)

Sujanitha UmamaheswaranLingegowda S. MangalaRobiya JosephNicholas B. JenningsMark S. KimYunfei WenEmine BayraktarNingyan ZhangZhiqiang AnAnil K. Sood

cancer researchcancer biologyovarian cancerimmunologyimmune suppression

Mechanism and Rational Combinations With Gp ‐2250, a Novel Oxathiazine Derivative, in Ovarian Cancer. Cancer Medicine (2024)

Abstract 2720: Enhancing Oral Delivery of Plant-Derived Vesicles. Cancer Research (2023)

plant-derived vesiclesoncologycancer researchcancer biologycancer carebiotechnologyhealth sciencesoral deliverydrug delivery

Abstract 528: Mechanisms and Rational Combinations With Gp-2250, a Novel Oxathiazine Derivative, in Ovarian Cancer. Cancer Research (2023)

Mark S. KimDeanna GlassmanAdrian Lankenau AhumadaEmine BayraktarNicholas B. JenningsRobiya JosephSanghoon LeeRobert L. ColemanAnil K. Sood

cancer researchcancer biologyovarian cancerbiochemistrygynecologic oncologynovel oxathiazine derivative

Data From Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. (2023)

gynecologytumor biologyuterine cancercancer biologycell biologybiologic effectspharmacology

Data From Cross-Talk Between Epha2 and Braf/Craf is a Key Determinant of Response to Dasatinib. (2023)

Data From Dll4 Inhibition Plus Aflibercept Markedly Reduces Ovarian Tumor Growth. (2023)

Data From Epha2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma. (2023)

cancer immunotherapygynecologic cancersoncologycancer researchendometrial carcinomaimmunologycancer treatmentdrug targetingtumor targetingantibody drug conjugategynecologic oncology

Data From Immunotherapy Targeting Folate Receptor Induces Cell Death Associated With Autophagy in Ovarian Cancer. (2023)

cancer immunotherapycell autophagyovarian cancerautophagyimmunotherapyimmunologyfolate receptor inducescell death

1
2
3
4
5
10
10 / page